ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-Anchored endothelial proteins

Biochemical Journal

Volumn 452, Issue 1, 2013, Pages 97-109

  Fröhlich, Camilla ^a   Klitgaard, Marie ^a   Noer, Julie B ^a   Kotzsch, Alexander ^b   Nehammer, Camilla ^a   Kronqvist, Pauliina ^d   Berthelsen, Jens ^b   Blobel, Carl ^c   Kveiborg, Marie ^a   Albrechtsen, Reidar ^a   Wewer, Ulla M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF TURKU   (Finland)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

A disintegrin and metalloproteinase 12 (ADAM12); Breast cancer; Ectodomain shedding; Endothelial cell; Tumour vasculature; Vascular endothelial cadherin (VE cadherin)

Indexed keywords

ADAM PROTEIN; ADAM12 PROTEIN; ANGIOPOIETIN RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING; TUMOR VASCULARIZATION;

ADAM PROTEINS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC;

ERINACEIDAE;

EID: 84876934727     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20121558     Document Type: Article

References (59)

1. Hanahan, D. and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
2. Groot, A. J. and Vooijs, M. A. (2012) The role of Adams in Notch signaling. Adv. Exp. Med. Biol. 727, 15-36
3. Nam, E. J. and Park, P. W. (2012) Shedding of cell membrane-bound proteoglycans. Methods Mol. Biol. 836, 291-305
4. Higashiyama, S., Nanba, D., Nakayama, H., Inoue, H. and Fukuda, S. (2011) Ectodomain shedding and remnant peptide signalling of EGFRs and their ligands. J. Biochem. 150, 15-22
5. Dreymueller, D., Pruessmeyer, J., Groth, E. and Ludwig, A. (2012) The role of ADAM-mediated shedding in vascular biology. Eur. J. Cell Biol. 91, 472-485
6. Edwards, D. R., Handsley, M. M. and Pennington, C. J. (2008) The ADAM metalloproteinases. Mol. Aspects Med. 29, 258-289
7. Kveiborg, M., Albrechtsen, R., Couchman, J. R. and Wewer, U. M. (2008) Cellular roles of ADAM12 in health and disease. Int. J. Biochem. Cell Biol. 40, 1685-1702
8. Gilpin, B. J., Loechel, F., Mattei, M. G., Engvall, E., Albrechtsen, R. and Wewer, U. M. (1998) A novel, secreted form of human ADAM 12 (meltrin α) provokes myogenesis in vivo. J. Biol. Chem. 273, 157-166
9. Frohlich, C., Albrechtsen, R., Dyrskjot, L., Rudkjaer, L., Orntoft, T. F. and Wewer, U. M. (2006) Molecular profiling of ADAM12 in human bladder cancer. Clin. Cancer Res. 12, 7359-7368
10. Roy, R., Wewer, U. M., Zurakowski, D., Pories, S. E. and Moses, M. A. (2004) ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J. Biol. Chem. 279, 51323-51330
11. Roy, R., Zurakowski, D., Pories, S., Moses, M. A. and Moss, M. L. (2011) Potential of fluorescent metalloproteinase substrates for cancer detection. Clin. Biochem. 44, 1434-1439
12. Frohlich, C., Nehammer, C., Albrechtsen, R., Kronqvist, P., Kveiborg, M., Sehara-Fujisawa, A., Mercurio, A. M. and Wewer, U. M. (2011) ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression. Mol. Cancer Res. 9, 1449-1461
13. Kveiborg, M., Frohlich, C., Albrechtsen, R., Tischler, V., Dietrich, N., Holck, P., Kronqvist, P., Rank, F., Mercurio, A. M. and Wewer, U. M. (2005) A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res. 65, 4754-4761
14. Peduto, L., Reuter, V. E., Sehara-Fujisawa, A., Shaffer, D. R., Scher, H. I. and Blobel, C. P. (2006) ADAM12 is highly expressed in carcinoma-Associated stroma and is required for mouse prostate tumor progression. Oncogene 25, 5462-5466
15. Roy, R., Rodig, S., Bielenberg, D., Zurakowski, D. and Moses, M. A. (2011) ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis. J. Biol. Chem. 286, 20758-20768
16. Ohlig, S., Farshi, P., Pickhinke, U., van den Boom, J., Hoing, S., Jakuschev, S., Hoffmann, D., Dreier, R., Scholer, H. R., Dierker, T. et al. (2011) Sonic hedgehog shedding results in functional activation of the solubilized protein. Dev. Cell 20, 764-774
17. Kodama, T., Ikeda, E., Okada, A., Ohtsuka, T., Shimoda, M., Shiomi, T., Yoshida, K., Nakada, M., Ohuchi, E. and Okada, Y. (2004) ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am. J. Pathol. 165, 1743-1753
18. Li, H., Duhachek-Muggy, S., Qi, Y., Hong, Y., Behbod, F. and Zolkiewska, A. (2012) An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer. Breast Cancer Res. Treat. 135, 759-769
19. Kveiborg, M., Jacobsen, J., Lee, M. H., Nagase, H., Wewer, U. M. and Murphy, G. (2010) Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). Biochem. J. 430, 79-86
20. Lee, M. H., Rapti, M. and Murphy, G. (2004) Delineating the molecular basis of the inactivity of tissue inhibitor of metalloproteinase-2 against tumor necrosis factor-α-converting enzyme. J. Biol. Chem. 279, 45121-45129
21. Iba, K., Albrechtsen, R., Gilpin, B., Frohlich, C., Loechel, F., Zolkiewska, A., Ishiguro, K., Kojima, T., Liu, W., Langford, J. K. et al. (2000) The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to β1 integrin-dependent cell spreading. J. Cell Biol. 149, 1143-1156
22. Sundberg, C., Thodeti, C. K., Kveiborg, M., Larsson, C., Parker, P., Albrechtsen, R. and Wewer, U. M. (2004) Regulation of ADAM12 cell-surface expression by protein kinase C epsilon. J. Biol. Chem. 279, 51601-51611
23. Loechel, F., Fox, J. W., Murphy, G., Albrechtsen, R. and Wewer, U. M. (2000) ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem. Biophys. Res. Commun. 278, 511-515
24. Moss, M. L. and Rasmussen, F. H. (2007) Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal. Biochem. 366, 144-148
25. Sanjay, A., Houghton, A., Neff, L., DiDomenico, E., Bardelay, C., Antoine, E., Levy, J., Gailit, J., Bowtell, D., Horne, W. C. and Baron, R. (2001) Cbl associates with Pyk2 and Src to regulate Src kinase activity, αvβ3 integrin-mediated signaling, cell adhesion, and osteoclast motility. J. Cell Biol. 152, 181-195
26. Sahin, U., Weskamp, G., Kelly, K., Zhou, H. M., Higashiyama, S., Peschon, J., Hartmann, D., Saftig, P. and Blobel, C. P. (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 164, 769-779
27. Williams, R. L., Risau, W., Zerwes, H. G., Drexler, H., Aguzzi, A. and Wagner, E. F. (1989) Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell 57, 1053-1063
28. Kawaguchi, N., Sundberg, C., Kveiborg, M., Moghadaszadeh, B., Asmar, M., Dietrich, N., Thodeti, C. K., Nielsen, F. C., Moller, P., Mercurio, A. M. et al. (2003) ADAM12 induces actin cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating β1 integrin function. J. Cell Sci. 116, 3893-3904
29. Stautz, D., Sanjay, A., Hansen, M. T., Albrechtsen, R., Wewer, U. M. and Kveiborg, M. (2010) ADAM12 localizes with c-Src to actin-rich structures at the cell periphery and regulates Src kinase activity. Exp. Cell Res. 316, 55-67
30. Chesneau, V., Becherer, J. D., Zheng, Y., Erdjument-Bromage, H., Tempst, P. and Blobel, C. P. (2003) Catalytic properties of ADAM19. J. Biol. Chem. 278, 22331-22340
31. Guaiquil, V., Swendeman, S., Yoshida, T., Chavala, S., Campochiaro, P. A. and Blobel, C. P. (2009) ADAM9 is involved in pathological retinal neovascularization. Mol. Cell. Biol. 29, 2694-2703
32. Horiuchi, K., Zhou, H. M., Kelly, K., Manova, K. and Blobel, C. P. (2005) Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins β1 and β2. Dev. Biol. 283, 459-471
33. Kawaguchi, N., Horiuchi, K., Becherer, J. D., Toyama, Y., Besmer, P. and Blobel, C. P. (2007) Different ADAMs have distinct influences on Kit ligand processing: phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by ADAM19. J. Cell Sci. 120, 943-952
34. Weskamp, G., Mendelson, K., Swendeman, S., Le Gall, S., Ma, Y., Lyman, S., Hinoki, A., Eguchi, S., Guaiquil, V., Horiuchi, K. and Blobel, C. P. (2010) Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ. Res. 106, 932-940
35. Lydolph, M. C., Morgan-Fisher, M., Hoye, A. M., Couchman, J. R., Wewer, U. M. and Yoneda, A. (2009) α9β1 integrin in melanoma cells can signal different adhesion states for migration and anchorage. Exp. Cell Res. 315, 3312-3324
36. Pennington, C. J. and Edwards, D. R. (2010) Real-time PCR expression profiling of MMPs and TIMPs. Methods Mol. Biol. 622, 159-173
37. Sasaroli, D., Gimotty, P. A., Pathak, H. B., Hammond, R., Kougioumtzidou, E., Katsaros, D., Buckanovich, R., Devarajan, K., Sandaltzopoulos, R., Godwin, A. K. et al. (2011) Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol. Ther. 12, 169-180
38. Lendeckel, U., Kohl, J., Arndt, M., Carl-McGrath, S., Donat, H. and Rocken, C. (2005) Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J. Cancer Res. Clin. Oncol. 131, 41-48
39. Jacobsen, J., Visse, R., Sorensen, H. P., Enghild, J. J., Brew, K., Wewer, U. M. and Nagase, H. (2008) Catalytic properties of ADAM12 and its domain deletion mutants. Biochemistry 47, 537-547
40. Solomon, E., Li, H., Muggy, S. D., Syta, E. and Zolkiewska, A. (2010) The role of SnoN in transforming growth factor β1-induced expression of metalloprotease-disintegrin ADAM12. J. Biol. Chem. 285, 21969-21977
41. Guaiquil, V. H., Swendeman, S., Zhou, W., Guaiquil, P., Weskamp, G., Bartsch, J. W. and Blobel, C. P. (2010) ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. J. Mol. Med. 88, 497-505
42. Le Pabic, H., Bonnier, D., Wewer, U. M., Coutand, A., Musso, O., Baffet, G., Clement, B. and Theret, N. (2003) ADAM12 in human liver cancers: TGF-β-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 37, 1056-1066
43. Pollard, S. M., Wallbank, R., Tomlinson, S., Grotewold, L. and Smith, A. (2008) Fibroblast growth factor induces a neural stem cell phenotype in foetal forebrain progenitors and during embryonic stem cell differentiation. Mol. Cell. Neurosci. 38, 393-403
44. Baertling, F., Kokozidou, M., Pufe, T., Clarner, T., Windoffer, R., Wruck, C. J., Brandenburg, L. O., Beyer, C. and Kipp, M. (2010) ADAM12 is expressed by astrocytes during experimental demyelination. Brain Res. 1326, 1-14
45. Schulz, B., Pruessmeyer, J., Maretzky, T., Ludwig, A., Blobel, C. P., Saftig, P. and Reiss, K. (2008) ADAM10 regulates endothelial permeability and T-cell transmigration by proteolysis of vascular endothelial cadherin. Circ. Res. 102, 1192-1201
46. Sidibe, A., Mannic, T., Arboleas, M., Subileau, M., Gulino-Debrac, D., Bouillet, L., Jan, M., Vandhuick, T., Le Loet, X., Vittecoq, O. and Vilgrain, I. (2012) Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor α-induced VE-cadherin cleavage. Arthritis Rheum. 64, 77-87
47. Roy, R. and Moses, M. A. (2012), ADAM12: a novel mediator of tumor angiogenesis. In Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, Chicago, IL, U.S.A., 31 March-4 April 2012, Abstract 5285
48. Dymicka-Piekarska, V., Guzinska-Ustymowicz, K., Kuklinski, A. and Kemona, H. (2012) Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients. Thromb. Res. 129, e47-e50
49. Denduluri, N., Yang, S. X., Berman, A. W., Nguyen, D., Liewehr, D. J., Steinberg, S. M. and Swain, S. M. (2008) Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol. Ther. 7, 15-20
50. Reusch, P., Barleon, B., Weindel, K., Martiny-Baron, G., Godde, A., Siemeister, G. and Marme, D. (2001) Identification of a soluble form of the angiopoietin receptor TIE-2 creleased from endothelial cells and present in human blood. Angiogenesis 4, 123-131
51. Harris, A. L., Reusch, P., Barleon, B., Hang, C., Dobbs, N. and Marme, D. (2001) Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin. Cancer Res. 7, 1992-1997
52. Habibagahi, Z., Habibagahi, M. and Heidari, M. (2010) Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behcet's disease. Mod. Rheumatol. 20, 154-159
53. Soeki, T., Tamura, Y., Shinohara, H., Sakabe, K., Onose, Y. and Fukuda, N. (2004) Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis. Circ. J. 68, 1-5
54. Olsson, A. K., Dimberg, A., Kreuger, J. and Claesson-Welsh, L. (2006) VEGF receptor signalling: in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359-371
55. Fukuhara, S., Sako, K., Minami, T., Noda, K., Kim, H. Z., Kodama, T., Shibuya, M., Takakura, N., Koh, G. Y. and Mochizuki, N. (2008) Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat. Cell Biol. 10, 513-526
56. Findley, C. M., Cudmore, M. J., Ahmed, A. and Kontos, C. D. (2007) VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler., Thromb., Vasc. Biol. 27, 2619-2626
57. Onimaru, M., Yonemitsu, Y., Suzuki, H., Fujii, T. and Sueishi, K. (2010) An autocrine linkage between matrix metalloproteinase-14 and Tie-2 via ectodomain shedding modulates angiopoietin-1-dependent function in endothelial cells. Arterioscler., Thromb., Vasc. Biol. 30, 818-826
58. Saftig, P. and Reiss, K. (2011) The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potentiaľ Eur. J. Cell Biol. 90, 527-535
59. Coussens, L. M., Fingleton, B. and Matrisian, L. M. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392